The combined company will focus on advancing Serina’s SER-227 for treating advanced Parkinson’s disease. Credit: Ground Picture/Shutterstock.com.

US-based clinical-stage biotechnology company Serina Therapeutics has entered an agreement to merge with AgeX Therapeutics’ wholly-owned subsidiary.

Serina’s stockholders will receive AgeX common stock shares and the combined company will continue under the name Serina Therapeutics.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It will focus on advancing pre-clinical studies of Serina’s lead drug candidate SER-227 (POZ-buprenorphine) for treating advanced Parkinson’s disease.

The aim is to submit an investigational new drug (IND) application to the US Food and Drug Administration to commence a Phase I trial in the fourth quarter of 2024.

The combined company will also expand Serina’s lipid nanoparticles and antibody drug conjugates by collaborating with other partners.

See Also:

Serina Therapeutics board chair and co-founder Milton Harris stated: “The merger with AgeX positions Serina to advance our CNS pipeline assets and expand our platform partnering opportunities.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We believe it represents the best path forward for Serina in accessing transformative capital to advance our platform technology.

“As a board director of the combined company, I look forward to collaborating with our new partners AgeX and Juvenescence, as we continue the work of translating our science into innovative therapeutics.”

The merger will conclude in the first quarter of 2024.

Pre-merger AgeX stockholders will own 25% of the new combined entity while pre-merger Serina stockholders will own 75%.

Serina is planning to submit IND applications for SER-227 for post-operative pain indications and for SER-228 (POZ-cannabidiol) for refractory epilepsy indications.